News and Announcements
Viralytics (ASX:VLA) – Investor and Shareholder Presentation
- Published July 23, 2013 10:53AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Viralytics is an Australian Stock Exchange listed company developing a portfolio of Oncolytic viruses that have the potential not only to provide a more effective treatment of a range of cancers, but also a substantial improvement in patients quality of life. Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics’ headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia.
Viralytics lead product CAVATAK™ has now entered the global phase II stage of clinical trial development with recruitment ongoing for a Phase II trial, treating Late Stage Melanoma patients – the CALM study. Viralytics New Drug (IND) application was allowed by the USA FDA, enabling this trial to be commenced in the USA during 2011. The Phase II trial will investigate the effectiveness of intratumourally administered CAVATAK™ in the treatment of Late Stage Melanoma.
Download the latest Investor & Shareholder Presentation below.